Supernus Pharmaceuticals (SUPN) Set to Post Quarterly Earnings on Thursday

Supernus Pharmaceuticals (NASDAQ:SUPN) is expected to be announcing its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect Supernus Pharmaceuticals to announce earnings of $0.49 per share and revenue of $217.56 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). The company had revenue of $219.06 million during the quarter, compared to analyst estimates of $205.31 million. Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The business’s revenue was up 32.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.40 earnings per share. On average, analysts expect Supernus Pharmaceuticals to post $2.05 EPS for the current fiscal year and $3.95 EPS for the next fiscal year.

Supernus Pharmaceuticals Trading Down 0.0%

NASDAQ:SUPN opened at $41.21 on Thursday. The firm has a market capitalization of $2.40 billion, a PE ratio of -21.46, a price-to-earnings-growth ratio of 1.06 and a beta of 0.55. The stock has a 50 day moving average of $43.36 and a 200-day moving average of $46.16. Supernus Pharmaceuticals has a 52 week low of $37.54 and a 52 week high of $59.68.

Analysts Set New Price Targets

SUPN has been the topic of several recent research reports. Wall Street Zen downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Zacks Research lowered Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, October 5th. Cantor Fitzgerald upped their price objective on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, September 21st. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $62.40.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company’s activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.

Supernus’ marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older.